Andere talen ClearPoint Neuro, Inc.

Aandelen

CLPT

US18507C1036

Geschatte realtime Cboe BZX Andere beurzen 21:18:35 19-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
5,295 ^USD	-1,76%		-9,29%	-22,39%

13/03	CLEARPOINT NEURO, INC. : Stifel Nicolaus geeft koopadvies	ZM
12/03	ClearPoint Neuro, Inc. rapporteert resultaten voor het volledige jaar dat eindigde op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

GNW-Adhoc: ClearPoint Neuro beglückwünscht seinem Partner AviadoBio zur Behandlung des ersten Patienten in der klinischen Studie ASPIRE-FTD, in der AVB-101 für frontotemporale Demenz mit GRN-Mutationen evaluiert wird	17/04
ClearPoint Neuro si congratula con il proprio partner AviadoBio per il primo paziente trattato nello studio clinico ASPIRE-FTD, che valuta la terapia genica sperimentale AVB-101 per la demenza frontotemporale con mutazioni GRN	17/04
ClearPoint Neuro félicite son partenaire AviadoBio pour son premier patient traité dans le cadre de son essai clinique ASPIRE-FTD évaluant l’AVB-101 dans la démence fronto-temporale avec mutations du gène GRN	17/04
ClearPoint Neuro felicita a su socio AviadoBio por el primer paciente tratado en su ensayo clínico ASPIRE-FTD que evalúa AVB-101 en personas con demencia frontotemporal con mutaciones en el gen GRN	17/04
ClearPoint Neuro beglückwünscht seinem Partner AviadoBio zur Behandlung des ersten Patienten in der klinischen Studie ASPIRE-FTD, in der AVB-101 für frontotemporale Demenz mit GRN-Mutationen evaluiert wird	17/04
ClearPoint Neuro Says Partner AviadoBio Treats First Person in Trial of AVB-101 for Frontotemporal Dementia	16/04
ClearPoint Neuro Congratulates its Partner AviadoBio on First Patient Treated in its ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations	16/04
Purcell & Lefkowitz LLP Announces Shareholder Investigation of ClearPoint Neuro, Inc. (NASDAQ: CLPT)	08/04
ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza as a Treatment for AADC Deficiency	20/03
ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza™ as a Treatment for AADC Deficiency	19/03
ClearPoint Neuro, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	12/03
Earnings Flash (CLPT) CLEARPOINT NEURO Posts Q4 Revenue $6.8M, vs. Street Est of $6.5M	12/03
ClearPoint Neuro Reports Fourth Quarter and Full-Year 2023 Results	12/03
ClearPoint Neuro, Inc. Reaffirms Revenue Guidance for the Year 2024	12/03
Journal of Neurosurgery Publication Demonstrates Distinct Advantages of ClearPoint Prism® Neuro Laser Therapy System	11/03
ClearPoint Neuro, Inc. Announces Preclinical Results of an in Vivo Validation Study Have Been Published in the Journal of Neurosurgery	11/03
ClearPoint Neuro to Announce Fourth Quarter and Full Year 2023 Results March 12, 2024	04/03
ClearPoint Neuro to Announce Fourth Quarter and Full Year 2023 Results March 12, 2024	01/03
ClearPoint Neuro Announces Pricing of Public Offering of 2,307,694 Shares of Common Stock	01/03
ClearPoint Neuro to Seek Acquisitions	01/03

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen ClearPoint Neuro, Inc.

Aandelen

CLPT

US18507C1036

Andere talen

Filters